Immune checkpoint inhibitor-related endocrine diseases
Conditions
Interventions
Patients with pituitary related adverse reactions induced by anti PD-1 monoclonal antibody:N/A
Sponsors
The Third Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. History of anti-PD-1 monoclonal antibody application; 2. Normal pituitary function before anti-PD-1 monoclonal antibody treatment and normal pituitary morphology on MRI; 3. Nausea, vomiting, loss of appetite, fever, malaise, headache, eye muscle palsy, loss of vision and/or visual field defects, coma, etc. after anti-PD-1 monoclonal antibody treatment; 4. Pituitary hormone basal values below normal after treatment and pituitary hormone levels cannot be excited by hormone excitation test; 5. Imaging: with/without pituitary enlargement and no signs of tumor brain metastasis.
Exclusion criteria
Exclusion criteria: 1. Patients with brain metastases from primary tumor lesions, pituitary tumors, craniopharyngiomas, intracranial germ cell tumors, Langerhans cell histiocytosis, nodal disease, granulomatous vasculitis, systemic lupus erythematosus, tuberculosis, syphilis, and other intracranial localized occurrences and secondary pituitary inflammation due to systemic systemic immune diseases involving the pituitary gland; 2. Patients requiring tyrosine kinase inhibitors, requiring long-term massive glucocorticoid therapy, and severe adverse effects in other organs after ICPis therapy, such as ICPis-related myocarditis, hepatitis, pneumonia, and enterocolitis requiring moderate to high doses of glucocorticoid therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gender;Age;Thyroid stimulating hormone;Adrenocorticotropic hormone;Luteinizing hormone;Follicle-stimulating hormone; | — |
Countries
China
Contacts
Public ContactShuchang Wang
The Third Hospital of Hebei Medical University
Outcome results
None listed